DE3889138T2 - Influenza-Impfstoff. - Google Patents

Influenza-Impfstoff.

Info

Publication number
DE3889138T2
DE3889138T2 DE3889138T DE3889138T DE3889138T2 DE 3889138 T2 DE3889138 T2 DE 3889138T2 DE 3889138 T DE3889138 T DE 3889138T DE 3889138 T DE3889138 T DE 3889138T DE 3889138 T2 DE3889138 T2 DE 3889138T2
Authority
DE
Germany
Prior art keywords
vaccine
strain
cell
influenza vaccine
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3889138T
Other languages
English (en)
Other versions
DE3889138D1 (de
Inventor
John Sydney Oxford
James Searl Robertson
Geoffrey Christopher Schild
David Arthur John Tyrrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Publication of DE3889138D1 publication Critical patent/DE3889138D1/de
Application granted granted Critical
Publication of DE3889138T2 publication Critical patent/DE3889138T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE3889138T 1987-02-18 1988-02-04 Influenza-Impfstoff. Expired - Fee Related DE3889138T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878703696A GB8703696D0 (en) 1987-02-18 1987-02-18 Influenza vaccine

Publications (2)

Publication Number Publication Date
DE3889138D1 DE3889138D1 (de) 1994-05-26
DE3889138T2 true DE3889138T2 (de) 1994-08-04

Family

ID=10612471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3889138T Expired - Fee Related DE3889138T2 (de) 1987-02-18 1988-02-04 Influenza-Impfstoff.

Country Status (9)

Country Link
US (1) US5162112A (de)
EP (1) EP0279563B1 (de)
JP (1) JP2525734B2 (de)
AT (1) ATE104698T1 (de)
AU (1) AU613012B2 (de)
CA (1) CA1335790C (de)
DE (1) DE3889138T2 (de)
ES (1) ES2052699T3 (de)
GB (2) GB8703696D0 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374717A (en) * 1992-09-30 1994-12-20 The United States Of America As Represented By The Secretary Of Health And Human Services Sequences of the hemagglutinins of recent strains of influenza type B virus
EP0711340A4 (de) * 1993-06-11 1998-02-04 Peter M Palese Hohe ausbeuten an influenzenvirus
FR2761698B1 (fr) * 1997-04-04 1999-05-07 Pasteur Merieux Serums Vacc Methode de titrage d'une composition virale complexe
KR20070058440A (ko) * 2004-07-02 2007-06-08 헨리 엘 니만 복제 선택 재조합 및 그것의 용도
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
ES2694805T7 (es) 2006-09-11 2021-10-21 Seqirus Uk Ltd Fabricación de vacunas contra virus de la gripe sin usar huevos
SG177141A1 (en) * 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008153236A1 (en) * 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
WO2009081172A1 (en) * 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US20130039943A1 (en) * 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
BR112013010830A2 (pt) * 2010-11-02 2017-12-12 Hector Manuel Zepeda Lopez vacina inovadoras contra o vírus da influenza pandêmica a/h1n1
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US9579374B2 (en) * 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE662899A (de) * 1964-04-22
US4040905A (en) * 1971-10-27 1977-08-09 The United States Government Sub-human primate diploid cell lines as substrates for virus vaccine production

Also Published As

Publication number Publication date
GB2202327B (en) 1991-05-15
JPS63264532A (ja) 1988-11-01
GB8802507D0 (en) 1988-03-02
JP2525734B2 (ja) 1996-08-21
DE3889138D1 (de) 1994-05-26
US5162112A (en) 1992-11-10
GB8703696D0 (en) 1987-03-25
EP0279563A3 (en) 1989-10-25
ATE104698T1 (de) 1994-05-15
AU1191188A (en) 1988-08-25
GB2202327A (en) 1988-09-21
EP0279563B1 (de) 1994-04-20
ES2052699T3 (es) 1994-07-16
AU613012B2 (en) 1991-07-25
CA1335790C (en) 1995-06-06
EP0279563A2 (de) 1988-08-24

Similar Documents

Publication Publication Date Title
DE3889138D1 (de) Influenza-Impfstoff.
Stephenson et al. Antigenic relationships between measles and canine distemper viruses: comparison of immune response in animals and humans to individual virus-specific polypeptides.
Wambura et al. Experimental trials with a thermostable Newcastle disease virus (strain I2) in commercial and village chickens in Tanzania
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
ATE46920T1 (de) Viren und impfstoffe.
Charlton et al. Skunk rabies
Henle et al. A skin test for infectious hepatitis.
Kohl et al. Ontogeny of murine cellular cytotoxicity to herpes simplex virus-infected cells
Brugh et al. Emergence of highly pathogenic virus during selective chicken passage of the prototype mildly pathogenic chicken/Pennsylvania/83 (H5N2) influenza virus
ATE375T1 (de) Grippevirusimpfstoff und verfahren zu seiner herstellung.
Wenner et al. Propagation of group A coxsackie viruses in tissue cultures: II. Some interactions between virus and mammalian cells
GB1486186A (en) Vaccines against feline leukaemia and the group of diseases associated with feline leukaemis/virus infection
Berger An in vitro assay for quantifying the virus of avian encephalomyelitis
JPS5696692A (en) Novel influenza virus strain and influenza virus vaccine containing same
Shaw Cultivation of Coxsackie virus in embryonated eggs and in chick tissue cultures
ES2060740T3 (es) Vacunas de virus vivos para la enfermedad de newcastle.
DE2966648D1 (en) Vaccine against diseases caused by reo viruses, combined vaccine with newcastle disease virus, process for preparing them and reo virus strain used for their preparation
Huang et al. Association of avian reovirus M and S genes with viral behavior in vivo. I. Viral persistence
Mifune et al. Susceptibility of various cell lines to rabies virus
Spalatin et al. Recovery of a Newcastle Disease Virus Strain Indistinguishable from Texas GB
Kaminjolo Jr et al. Isolation, cultivation and characterization of a poxvirus from some horses in Kenya
Weremowicz et al. Laboratory investigations on equine influenza during the outbreak in Poland in 1980
SU908795A1 (ru) Штамм RавIеS VIRUS N777-м,используемый дл контрол иммуногенной активности антирабических вакцин
Janda et al. Variation in neurovirulence of NWS influenza virus after repeated passages in different tissue culture systems: I. Derivation and neurotropic activity of NWS virus lines
Al-Afaleq et al. Experimental inoculation of mice with trypsinresistant and trypsin-sensitive avian reoviruses

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee